6,000 inmates escape from prison during unrest in Mozambique
Arsenal made light work of Sporting CP as they left Lisbon with all three points to kick-start their Champions League campaign. Three goals before half-time did the damage, the first time they had scored three away goals in a European tie since Mikel Arteta's first season in charge. Goncalo Inacio threatened to make a game of it moments after the restart, but a Bukayo Saka penalty restored the three-goal advantage before Leandro Trossard scored the visitors' fifth. It was Arsenal's first away win in the Champions League in more than a year, with the last one comping against Sevilla in October 2023. It also helped them lay to rest the ghosts of their Europa League elimination against Sporting a few months before that. Both sides are now on 10 points from five European games, with automatic qualification for the round of 16 still a possibility. With two of the last three games on home soil, Arteta's men will fancy their chances. It took less than seven minutes for Arsenal to get themselves in front. Some quick passing down the Gunners right created space for Jurrien Timber, and his low cross found Gabriel Martinelli free at the back post to tap home. One became two just after the 20 minute mark, with more success down the right. This time it was Bukayo Saka who beat the offside trap and Kai Havertz who rolled the ball home from point-blank range. Gabriel headed home a Declan Rice corner seconds before the break, leaving Sporting with a mountain to climb. Inacio gave them hope, but it was quickly extinguished when Ousmane Diomande went through the back of Martin Odegaard and Saka made no mistake from the spot. Was this Arsenal's best performance of the season? Have your say in the comments section It was an important win for the visitors after they took just one point from their first two away European games, and Trossard made it absolutely safe as he tucked home the rebound after Mikel Merino's effort was parried. Here are Mirror Football 's talking points from the statement victory. While Manchester City were punished for missed chances at the Alvalade earlier in the month, Arsenal made no such mistake. Not only that, but they took advantage through the kind of goal which Pep Guardiola's side have made their bread and butter in recent years. An overload down the wing, followed by a cutback which leaves an free forward with a simple finish. Not once but twice, and Sporting had no answer. It almost happened for a third time before the break, with Kai Havertz inches from collecting a ball between the lines from Martin Odegaard. In the end, though, they went for a goal more typical of their own style - a header from a Rice corner. When Arsenal and Sporting met in the 2022-23 Europa League , Gabriel Martinelli ended up as the villain of the piece. His penalty was saved by Antonio Adan in a shoot-out defeat in North London, sending the Portuguese side through at the expense of Mikel Arteta's men. If that was playing on his mind at the start, that soon changed. He won't have too many easier finishes this season, but he still needed to be in the right place to meet Timber's low cross. The Brazilian hasn't been an automatic pick this season, with his goal tally below his previously high standards. This goal was vintage Martinelli, though, and he'll hope it can spur him on to more. Some eyebrows were raised when Arsenal fans looked at Mikel Arteta's weekend selection. Those players had more than enough to beat Nottingham Forest , though, and it allowed others to enjoy a bit of a rest. Martinelli was another of those given a rest over the weekend, and he made it count. It looked like a fresh team all round, too, with Arteta perhaps recognising the importance of a fast start. The flurry of goals also allowed Arteta to give some of his players an early rest, with Odegaard and Rice in particular likely to benefit from being kept fresh. Next for Arsenal is a trip to West Ham , who might have hoped to be facing a more tired opponent. William Saliba has felt like part of the furniture at Arsenal for so long, it's hard to remember a time when he wasn't a fixture in the side. It might seem strange, but he only made his first senior appearance less than two-and-a-half years ago and has now brought up 100 first-team outings. More than three quarters of those have come in the league, including all 38 last season. This was his 19th outing in Europe, and his first against Sporting since suffering the injury which curtailed his 2022-23 season. He put that memory behind him, marshalling the potentially dangerous Viktor Gyokeres. The victory was Saliba's 65th in 100 Arsenal outings, making him only the sixth player in the team's history to win as many during that first century of games. Going into Tuesday's game, Arsenal had failed to score in any of their last four away games in the Champions League . It almost cost them against Porto in last season's round of 16, and then did cost them against Bayern Munich in the quarter-finals as Thomas Tuchel's team followed a 2-2 first-leg draw with a 1-0 win in Bavaria. While the goalless draw against Atalanta this term wasn't the most inspiring display, the Gunners looked good value for a goal at the San Siro as they lost 1-0 to Inter. In short, many sensed that barren run wasn't likely to go on for too long. You have to go all the way back to 2008 for the last time Arsenal scored five in a European away day. They'd certainly have taken that before kick-off. Join our new WhatsApp community and receive your daily dose of Mirror Football content. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. If you're curious, you can read our Privacy Notice.Senate, Stakeholders Endorse Establishment Of Fed Poly Onueke
The Southwestern Athletic Conference has closed an investigation into an allegation that Jackson State improperly accessed practice footage of Arkansas-Pine Bluff prior to the teams' game on Nov. 2, it announced Tuesday. "After conducting a comprehensive review of the information received, which included an IT analysis provided by DVSportINC, both oral and written statements, written statements from both institutions, individual interviews, along with the consultation of legal counsel, the Conference Office does not have enough substantial evidence to prove any allegations of unethical conduct by Jackson State University," the conference said in a statement. Editor's Picks SWAC looking into claim of stolen practice film 4d Kyle Bonagura "The Southwestern Athletic Conference has officially concluded its investigation but reserves the right to review any additional information received on this matter." The allegation was first raised Oct. 31, when a UAPB player informed the coaching staff he was told by a Jackson State player that Tigers defensive players were in the Jackson State team facility watching practice film of UAPB from that week, sources told ESPN. After receiving this information, UAPB coach Alonzo Hampton logged into the software program the team uses to upload and review practice footage and saw that it had been accessed by the account of a former walk-on who had been cut in the spring, sources said. The IP address connected to the account when it accessed the practice video was assigned to Clinton, Mississippi, a town that neighbors Jackson, sources said. It is unclear who relayed this discovery to the conference office. Last week, after ESPN reported the allegation was being investigated, a spokesperson for Jackson State said the school had been informed the investigation was closed. However, a SWAC spokesperson told ESPN later in the day the investigation remained open after the conference had received additional information. The former walk-on told ESPN that he was contacted by UAPB coach Alonzo Hampton and UAPB athletic director Chris Robinson on Oct. 31. The former player spoke with ESPN on the condition his name would not be published, citing a desire to limit blowback in his direction. "[Hampton] let me know that my film has been accessed and I had logged in, and then he said he got word that Jackson State had been using the film," the player said. "He was persistent in thinking that I had released the film, and I repeated, 'No, I didn't release anything to Jackson State.'" Shortly after the former player spoke with Hampton, he received a call from Robinson in which he again denied having provided a password to anyone at Jackson State. ESPN reviewed the player's phone log to confirm the calls took place. As of Friday, the former player had not been interviewed by the SWAC, he said. The player reaffirmed to ESPN that he did not share his credentials with anyone at Jackson State but said he had shared that information with teammates at UAPB in the past and that there was a loose culture around sharing login information within the team. A source familiar with the video-sharing software cautioned against using the IP address as proof the film was accessed near Jackson, as various measures can be used to alter the location of an IP address. The software has a security feature that would have allowed UAPB to limit access for each account to specific devices, but it was not used. Jackson State (10-2, 7-0 SWAC) was a heavy favorite against UAPB (3-9, 2-6) and held the Golden Lions to their worst offensive performance since being shutout by Arkansas in the season opener. The Tigers will host Southern in the SWAC championship game on Dec. 7.
MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. NSPR , developer of the CGuardTM Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott ABT in April 2023. Paul Stuka, Chairman of the Board of InspireMD, stated, "We are extremely fortunate to add Scott to what I consider to be a world-class Board of Directors. With his extensive operational experience and track record in the cardiovascular space, his insights will be invaluable as the Company rapidly approaches potential U.S. approval of CGuard Prime, the most significant value inflection point in its history. I look forward to Scott's contributions and believe he will have an immediate impact." Marvin Slosman, Chief Executive Officer of InspireMD and Board member, commented, "The addition of Scott to our Board adds tremendous experience in the cardiovascular field, with a track record of growth and innovation as an executive, a board member and investor. His experience and legacy in the space will help guide us through our next stages of advancing our novel carotid platform as part of a comprehensive approach to catalyzing on the market shift toward a stent first standard while also guiding our pipeline of innovation, including our CAS, TCAR and Neuro focus." "I am very excited to join the InspireMD Board at such a transformational time for the company," added Mr. Ward. "With an impressive body of data demonstrating the superior short- and long-term patient outcomes of its novel CGuard Prime carotid stent system, I believe that CGuard, when approved in the U.S., will quickly become a new standard-of-care for carotid intervention and stroke prevention. I look forward to working with my fellow Board members and the InspireMD leadership team to achieve this goal." Mr. Ward has over 40 years of experience in the healthcare industry, including nearly 30 years at Medtronic, Inc. where he served in various leadership roles including as Senior Vice President and President of the CardioVascular, Neurological and Diabetes businesses. Mr. Ward is the Founder of Raymond Holdings, a firm with activities in venture capital, strategy and transactional advisory services for medical technology and life science companies. He earned his Bachelor of Science in Genetics and Cell Biology, his Master of Science in Toxicology, and his Master of Business Administration, all from the University of Minnesota. About InspireMD, Inc. InspireMD seeks to utilize its proprietary MicroNet ® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD's common stock is quoted on the Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com . Forward-looking Statements This press release contains "forward-looking statements." Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team's expectations, hopes, beliefs, intentions or strategies regarding the future. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential", "scheduled" or similar words. Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team's or directors' expectations, hopes, beliefs, intentions or strategies regarding future events, future financial performance, strategies, expectations, competitive environment and regulation, including potential U.S. commercial launch.. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company's control, and cannot be predicted or quantified and consequently; actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with our history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives, and substantial doubt regarding our ability to continue as a going concern; our need to raise additional capital to meet our business requirements in the future and such capital raising may be costly or difficult to obtain and could dilute our stockholders' ownership interests; market acceptance of our products; an inability to secure and maintain regulatory approvals for the sale of our products; negative clinical trial results or lengthy product delays in key markets; our ability to maintain compliance with the Nasdaq listing standards; our ability to generate revenues from our products and obtain and maintain regulatory approvals for our products; our ability to adequately protect our intellectual property; our dependence on a single manufacturing facility and our ability to comply with stringent manufacturing quality standards and to increase production as necessary; the risk that the data collected from our current and planned clinical trials may not be sufficient to demonstrate that our technology is an attractive alternative to other procedures and products; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; entry of new competitors and products and potential technological obsolescence of our products; inability to carry out research, development and commercialization plans; loss of a key customer or supplier; technical problems with our research and products and potential product liability claims; product malfunctions; price increases for supplies and components; insufficient or inadequate reimbursement by governmental and other third-party payers for our products; our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful; adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions; the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction; the escalation of hostilities in Israel, which could impair our ability to manufacture our products; and current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov . The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. Investor Contacts: Craig Shore Chief Financial Officer InspireMD, Inc. 888-776-6804 craigs@inspiremd.com Chuck Padala, Managing Director LifeSci Advisors 646-627-8390 chuck@lifesciadvisors.com investor-relations@inspiremd.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Everyone will love this Marry Me chicken budget meal